RPL21P13

Across TCGA pan-cancer cohorts, RPL21P13 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPL21P13 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RPL21P13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL21P13 expression acts as an unfavorable survival marker.

STAD, UCEC, and SKCM are the cancer types where RPL21P13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
UCEC	OS	Median	All	0.117	0.679	.001	30	view →
SKCM	OS	Median	III,IV	0.216	0.705	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPL21P13–STAD (OS)

Open the STAD breakdown →